Laboratory Co. of America (LH) to Release Earnings on Tuesday

Laboratory Co. of America (NYSE:LH) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of $3.75 per share and revenue of $3.41 billion for the quarter. Laboratory Co. of America has set its FY 2025 guidance at 15.600-16.400 EPS.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, analysts expect Laboratory Co. of America to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Laboratory Co. of America Stock Down 2.2 %

Laboratory Co. of America stock opened at $212.43 on Tuesday. The firm’s 50 day moving average price is $236.97 and its two-hundred day moving average price is $234.96. The firm has a market cap of $17.77 billion, a PE ratio of 24.09, a P/E/G ratio of 1.71 and a beta of 0.99. Laboratory Co. of America has a twelve month low of $191.97 and a twelve month high of $258.59. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.36%. Laboratory Co. of America’s dividend payout ratio is 32.65%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Redburn Atlantic began coverage on Laboratory Co. of America in a research note on Wednesday, April 2nd. They set a “buy” rating and a $276.00 price target for the company. Truist Financial reduced their target price on shares of Laboratory Co. of America from $285.00 to $274.00 and set a “buy” rating for the company in a research note on Friday, April 11th. Piper Sandler raised their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Barclays lowered their target price on shares of Laboratory Co. of America from $260.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Finally, StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a research note on Friday. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $268.77.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the transaction, the chief executive officer now owns 86,445 shares of the company’s stock, valued at approximately $21,146,175.90. This represents a 6.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the transaction, the executive vice president now owns 2,171 shares in the company, valued at approximately $545,572.30. The trade was a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,258 shares of company stock worth $3,518,177. 0.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Laboratory Co. of America

An institutional investor recently bought a new position in Laboratory Co. of America stock. Brighton Jones LLC bought a new position in Laboratory Co. of America Holdings (NYSE:LH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,321 shares of the medical research company’s stock, valued at approximately $991,000. 95.94% of the stock is currently owned by institutional investors.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.